C
CORMEDIX INC
NASDAQ: CRMD (CorMedix Inc.)
Last update: 12 hours ago7.72
-0.07 (-0.90%)
| Previous Close | 7.79 |
| Volume | 1,806,366 |
| Price / Earnings (Forward) | 47.17 |
| Price / Sales | 1.56 |
| Price / Book | 1.32 |
| 52 Weeks Range |
| Profit Margin | 20.81% |
| Operating Margin (TTM) | 51.49% |
| Diluted EPS (TTM) | 0.250 |
| Total Debt/Equity (MRQ) | 0.41% |
| Current Ratio (MRQ) | 4.21 |
| Operating Cash Flow (TTM) | -13.57 M |
| Levered Free Cash Flow (TTM) | -21.07 M |
| Return on Assets (TTM) | 8.31% |
| Return on Equity (TTM) | 19.87% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | CorMedix Inc. | Mixed | Bearish |
AIStockmoo Score
1.1
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 1.14 |
|
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.08% |
| % Held by Institutions | 34.20% |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |